Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors.
Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore.
Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes.
Multiple sclerosis.
Multiple sclerosis: Cognitive status declines on warmer days in patients with multiple sclerosis.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Proteomic analysis of the anti-inflammatory action of minocycline.
Long-term Analyses of Innervation and Neuromuscular Integrity in the Trembler-J Mouse Model of Charcot-Marie-Tooth Disease.
MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.
Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?
Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients.
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.
[Chronically Ill and Unemployed? A Review on Vocational Status in Multiple Sclerosis].
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
Selective depression of low-release probability excitatory synapses by sodium channel blockers.
Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis.
17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
The Sphingosine 1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Post-Infarction Left Ventricular Remodeling in a Porcine Model of Ischemia-Reperfusion.
Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.
[Central motor pathways in children with multiple sclerosis].
Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.

Pages